Esperion Therapeutics and Masimo are two companies that make medicines and machines to help people feel better or be healthy. Their stocks went up in value before the stock market opened today because they got good news from the government about their products. This made some people want to buy more of their stocks, so their prices increased. Read from source...

1. The title is misleading and does not reflect the main content of the article. It implies that Esperion Therapeutics, Masimo, and other big stocks are moving higher in the pre-market session, but it only mentions one company (Esperion Therapeutics) and its gains in the pre-market trading. The other companies mentioned in the article do not provide any information on their performance in the pre-market session. A better title would be "Esperion Therapeutics Soars In Pre-Market Trading After FDA Approval".
2. The article does not provide any context or background on Esperion Therapeutics, Masimo, or other big stocks mentioned in the pre-market session. It assumes that the readers are already familiar with these companies and their products, which may not be the case for many investors. A brief introduction to each company and their recent developments would help the readers understand the significance of the FDA approval and the market reaction better.
3. The article does not explain how the new labels for Esperion's NEXLETOL® and NEXLIZET® will benefit the company or its shareholders in the long run. It only states that they prevent heart attacks and cardiovascular procedures, but it does not provide any evidence or data to support this claim. Moreover, it does not address the potential side effects or risks associated with these drugs, which may affect their demand and profitability.
4. The article does not mention any other factors that may influence the pre-market trading session, such as news, events, earnings reports, analyst ratings, etc. It only focuses on the FDA approval and its impact on Esperion Therapeutics' shares. A more comprehensive analysis of the market conditions and trends would give a clearer picture of why these stocks are moving higher or lower in the pre-market session.
5. The article does not provide any sources or references for its information, which makes it difficult to verify its accuracy and credibility. It also uses vague and ambiguous terms, such as "shar" (which seems to be a typo), "big stocks", "pre-market session", etc., which do not convey clear or precise meanings. A more professional and consistent writing style would improve the quality and clarity of the article.

Esperion Therapeutics (NASDAQ:ESPR) - Buy, high risk, potential for significant gains if FDA approval leads to increased demand and market share.
Masimo (NASDAQ:MASI) - Hold, moderate risk, stable performance with room for growth in healthcare sector.
Forge Global Holdings (NYSE:FORG) - Sell, high risk, volatile stock price due to regulatory uncertainties and competition from other platforms.